Tamarixetin

Tamarixetin

SCHEMBL892776

COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 8/20 1.00
CYP1A1 P04798 7/20 1.00
CYP1B1 Q16678 7/20 1.00
XDH P47989 6/20 0.84
DPP4 P27487 4/20 0.84
MEN1 O00255 8/20 0.82
KMT2A Q03164 8/20 0.82
IPMK Q8NFU5 6/20 0.82
IP6K2 Q9UHH9 6/20 0.82
CA12 O43570 3/20 0.82
CA2 P00918 3/20 0.82
PPARG P37231 3/20 0.82
CA7 P43166 3/20 0.82
CA4 P22748 2/20 0.82
TUBB4A P04350 1/20 0.80
TUBB P07437 1/20 0.80
TUBA3C P0DPH7 1/20 0.80
TUBA1B P68363 1/20 0.80
TUBA4A P68366 1/20 0.80
TUBB4B P68371 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tamarixetin SCHEMBL29750609 1.00 CYP1A2 (1.00) CYP1A2CYP1A1CYP1B1XDHDPP4
Tamarixetin SCHEMBL30255798 1.00 CYP1A2 (1.00) CYP1A2CYP1A1CYP1B1XDHDPP4
SCHEMBL30256517 0.93 MEN1 (0.86) CYP1A2CYP1A1CYP1B1XDHDPP4
SCHEMBL29575749 0.93 MEN1 (0.86) CYP1A2CYP1A1CYP1B1XDHDPP4
SCHEMBL3211188 0.93 MEN1 (0.86) CYP1A2CYP1A1CYP1B1XDHDPP4
Ombuine SCHEMBL29475881 0.91 XDH (1.00) CYP1A2CYP1A1CYP1B1XDHDPP4
Ombuine SCHEMBL1252211 0.91 XDH (1.00) CYP1A2CYP1A1CYP1B1XDHDPP4
Ombuine SCHEMBL31516400 0.91 XDH (1.00) CYP1A2CYP1A1CYP1B1XDHDPP4
Isorhamnetin SCHEMBL19235 0.90 MEN1 (1.00) CYP1A2CYP1A1CYP1B1XDHDPP4
Isorhamnetin SCHEMBL30385934 0.90 MEN1 (1.00) CYP1A2CYP1A1CYP1B1XDHDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12514278-B2 Tobacco-derived composition R.J. REYNOLDS TOBACCO COMPANY (US) 2026-01-06 US claimed
EP-4655410-A2 O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE Symrise AG (DE) 2025-12-03 EP claimed
US-20250042765-A1 METHOD FOR TREATING A SURFACE CONTAMINATED WITH PSEUDOMONAS AERUGINOSA IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2025-02-06 US claimed
US-12157677-B2 Method for treating a biologically contaminated surface IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-12-03 US claimed
WO-2024156359-A1 O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE SYMRISE AG (DE) 2024-08-02 WO claimed
WO-2024156879-A2 O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE SYMRISE AG (DE) 2024-08-02 WO claimed
EP-4401713-A1 ALIMENTARY-RELATED PARTICLES, PRODUCTION METHODS, AND PRODUCTION APPARATUS Nulixir Inc. (US) 2024-07-24 EP claimed
EP-4401712-A1 ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MAKING THE SAME Nulixir Inc. (US) 2024-07-24 EP claimed
EP-4401711-A1 STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME Nulixir Inc. (US) 2024-07-24 EP claimed
EP-4401714-A1 ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME Nulixir Inc. (US) 2024-07-24 EP claimed
US-20130184227-A1 Cytochrome P450 2C9 Inhibitors HU OLIVER YOA-PU (TW) 2013-07-18 US claimed
WO-2013037603-A1 QUERCETIN FOR BROWNING FOOD SURFACES NESTEC S.A. (CH) 2013-03-21 WO claimed
US-8304394-B2 Low side effect pharmaceutical composition containing isoniazid NATIONAL DEFENSE EDUCATION AND RESEARCH FOUNDATION (TW) 2012-11-06 US claimed
US-20110207684-A1 NEW LOW SIDE EFFECT PHARMACEUTICAL COMPOSITION CONTAINING ISONIAZID NATIONAL DEFENSE EDUCATION AND RESEARCH FOUNDATION (TW) 2011-08-25 US claimed
US-20110034427-A1 Anti-aging properties of quercetin, 18alpha-glycyrrhetinic acid and hederagenin and their derivatives KORRES S.A. NATURAL PRODUCTS (GR) 2011-02-10 US claimed
EP-1569628-B1 NOVEL USE OF LYCOPENE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ANDROGEN SIGNALLING DSM IP ASSETS BV (NL) 2009-07-22 EP claimed
US-20060069042-A1 Cytochrome P450 2C9 inhibitors NATIONAL DEFENSE MEDICAL CENTER (TW) 2006-03-30 US claimed
CN-1720030-A The new purposes of lycopene DSM IP ASSETS BV (NL) 2006-01-11 CN claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
US-5631038-A COMPOUNDS (TASTANDS) TO REDUCE OR ELIMINATE A BITTER OR METALLIC TASTE ARE ADDED TO FOODS CONTAINING SODIUM CHLORIDE BIORESEARCH, INC. (US) 1997-05-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034427-A1 Anti-aging properties of quercetin, 18alpha-glycyrrhetinic acid and hederagenin and their derivatives GLA, AGER, CUTA CYP1A2 1047/4885CYP1A1 1329/4885CYP1B1 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.